Indication

Desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. The use of imlifidase should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Medicine details

Medicine name:
imlifidase (Idefirix)
SMC ID:
SMC2445
Pharmaceutical company
Hansa Biopharma
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
02 May 2022